SEARCH

SEARCH BY CITATION

References

  • Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K et al. (2003). Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9: 13701376.
  • Athyros VG, Papageorgiou AA, Mercouris BR, Athyrou W, Symeonidis AN, Basayannis EO et al. (2002). Treatment with atorvastatin to the National Cholesterol Educational Program goal versus ‘usual’ care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin 18: 220228.
  • Axel DI, Riessen R, Runge H, Viebahn R, Karsch KR (2000). Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol 35: 619629.
  • Bendermacher BL, Willigendael EM, Teijink JA, Prins MH (2005). Medical management of peripheral arterial disease. J Thromb Haemost 3: 16281637.
  • Boodhwani M, Nakai Y, Voisine P, Feng J, Li J, Mieno S et al. (2006). High-dose atorvastatin improves hypercholesterolemic coronary endothelial dysfunction without improving the angiogenic response. Circulation 114 (Suppl I): I402I408.
  • Brouet A, Sonveaux P, Dessy C, Moniotte S, Balligand JL, Feron O (2001). Hsp90 and caveolin are key targets for the proangiogenic nitric-oxide-mediated effects of statins. Circ Res 89: 866873.
  • Cai S, Khoo J, Mussa S, Alp NJ, Channon KM (2005). Endothelial nitric oxide synthase dysfunction in diabetic mice: importance of tetrahydrobiopterin in eNOS dimerisation. Diabetologia 48: 19331940.
  • Collins R, Armitage J, Parish S, Sleigh P, Peto R, Heart Protection Study Collaborative Group (2003). MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 20052016.
  • Dever G, Spickett CM, Kennedy S, Monopoli A, Wainwright CL (2006). The NO-donating pravastatin derivative (NCX 6550) reduces splenocyte adhesion and ROS generation in normal and atherosclerotic mice. JPET, (in press).
  • Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M et al. (2001). HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 108: 391397.
  • Dimmeler S, Fisslthaler B, Fleming I, Hermann C, Busse R, Zeiher AM (1999). Activation of nitric oxide synthase in endothelial cells via Akt-dependent phosphorylation. Nature 399: 601605.
  • Dincer I, Ongun A, Turhan S, Ozdol C, Ertas F, Erol C (2006). Effect of statin treatment on coronary collateral development in patients with diabetes mellitus. Am J Cardiol 97: 772774.
  • Edwards PA, Ericsson J (1999). Sterols and isoprenoids: signaling molecules derived from the cholesterol biosynthetic pathway. Annu Rev Biochem 68: 157185.
  • Emanueli C, Graiani G, Salis MB, Gadau S, Desortes E, Madeddu P (2004a). Prophylactic gene therapy with human tissue kallikrein ameliorates limb ischemia recovery in type 1 diabetic mice. Diabetes 53: 10961103.
  • Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB et al. (2001). Local delivery of human tissue kallikrein gene accelerates spontaneous angiogenesis in a mouse model of hindlimb ischemia. Circulation 103: 125132.
  • Emanueli C, Minasi A, Zacheo A, Chao J, Chao L, Salis MB et al. (2002a). Nerve growth factor promotes angiogenesis and arteriogenesis in ischemic hindlimbs. Circulation 106: 22572262.
  • Emanueli C, Salis B, Stacca T, Pinna A, Gaspa L, Madeddu P (2002b). Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia. Br J Pharmacol 135: 8792.
  • Emanueli C, Salis MB, Van Linthout S, Meloni M, Desortes E, Silvestre JS et al. (2004b). Akt/protein kinase B and endothelial nitric oxide synthase mediate muscular neovascularization induced by tissue kallikrein gene transfer. Circulation 110: 16381644.
  • Emanueli C, Van Linthout S, Salis MB, Monopoli A, Del Soldato P, Ongini E et al. (2004c). Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia. Arterioscler Thromb Vasc Biol 24: 20822087.
  • Feleszko W, Balkowiec EZ, Sieberth E, Marczak M, Dabrowska A, Giermasz A et al. (1999). Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis. Int J Cancer 81: 560567.
  • Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K et al. (1999). Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399: 597601.
  • Heller R, Polack T, Grabner R, Till U (1999). Nitric oxide inhibits proliferation of human endothelial cells via a mechanism independent of cGMP. Atherosclerosis 144: 4957.
  • Kraenkel N, Adams V, Linke A, Gielen S, Erb S, Lenk K et al. (2005). Hyperglycemia reduces survival and impairs function of circulating blood-derived progenitor cells. Arterioscler Thromb Vasc Biol 25: 698703.
  • Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ et al. (2000). The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6: 10041010.
  • Laufs U, Liao JK (1998). Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 2426624271.
  • Lewis SJ, Moye LA, Sacks FM, Johnstone DE, Timmis G, Mitchell J et al. (1998). Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial. Ann Intern Med 129: 681689.
  • Llevadot J, Murasawa S, Kureishi Y, Uchida S, Masuda H, Kawamoto A et al. (2001). HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest 108: 399405.
  • Loomans CJ, de Koning EJ, Staal FJ, Rookmaaaker MB, Verseyden C, de Boer HC et al. (2004). Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes. Diabetes 53: 195199.
  • Maron DJ, Fazio S, Linton MF (2000). Current perspectives on statins. Circulation 101: 207213.
  • Mohler ER, Hiatt WR, Creager MA, The Study Investigators (2003). Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral disease. Circulation 108: 14811486.
  • MRC/BHF (2002). Heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomised placebo-controlled trial. Heart Protection Study Collaborative Group. Lancet 360: 722.
  • Muscara M, McKnight W, Del Soldato P, Wallace J, Lovren F, Dicay M et al. (2001). Vasorelaxant effects of a nitric-oxide-releasing aspirin derivative in normotensive and hypertensive rats. Br J Pharmacol 133: 13141322.
  • Namba T, Koike H, Murakami K, Aoki M, Makino H, Hashiya N et al. (2003). Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108: 22502257.
  • Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH (1997). Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochim Biophys Acta 1345: 259268.
  • Ongini E, Impagnatiello F, Bonazzi A, Guzzetta M, Govoni M, Monopoli A et al. (2004). Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties. Proc Natl Acad Sci USA 101: 84978502.
  • Presotto C, Miglietta R, Olivieri A, Monopoli A (2005). The nitropravastatin derivative, NCX 6550, improves endothelial dysfunction in spontaneously hypertensive rats. Circulation 112 (Suppl II): 17.
  • Rivard A, Silver M, Chen D, Kearney M, Magner M, Annex B et al. (1999). Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154: 355363.
  • Rossiello MR, Momi S, Caracchini R, Giannini S, Guglielmini G, Monopoli A et al. (2005). A novel nitric oxide-releasing statin derivative exerts an antiplatelet/antithrombotic activity and inhibits tissue factor expression. J Thrombosis Haemostasis 3: 25542562.
  • Sata M, Nishimatsu H, Osuga J, Tanaka K, Ishizaka N, Ishibashi S et al. (2004). Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension 43: 2141220.
  • Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y et al. (2001). Endothelial nitric oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 15: 25302532.
  • Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. (2003). ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 36: 11491158.
  • Smith Jr RS, Lin KF, Agata J, Chao L, Chao J (2002). Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 22: 127912850.
  • Tsurumi Y, Murohara T, Krasinski K, Chen D, Witzenbichler B, Kearney M (1997). Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat Med 3: 879886.
  • Vincent L, Chen W, Hong L, Mirshahi F, Mishal Z, Mirshahi-Khorassani T et al. (2001). Inhibition of endothelial cell migration by cerivastatin, an HMG-CoA reductase inhibitor: contribution to its anti-angiogenic effect. FEBS Lett 495: 159166.
  • Vincent L, Soria C, Mirshahi F, Opolon P, Mishal Z, Vannier JP et al. (2002). Cerivastatin, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase, inhibits endothelial cell proliferation induced by angiogenic factors in vitro and angiogenesis in in vivo models. Arterioscler Thromb Vasc Biol 22: 623629.
  • Weis M, Heeschen C, Glass AJ, Cooke JP (2002). Statins have a biphasic effects on angiogenesis. Circulation 105: 739745.